Biochemical criteria of toxicity of therapy with high doses of methotrexate in children with osteosarcoma
Methotrexate (Mtx) is a cytotoxic drug from the group of antimetabolites, folic acid antagonists. High-dose (HD) Mtx in pediatric oncology are used for the treatment of osteosarcoma (OS), and other types of tumors. This therapy has allowed to achieve a five-year relapse-free survival rates up to 80...
Saved in:
| Main Authors: | A. M. Strizhevskaya, E. G. Golovnya, A. Z. Dzampaev, V. N. Baykova |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-06-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic drug monitoring of methotrexate after its administration in high doses for osteosarcoma treatment in children
by: A. M. Strizhevskaya, et al.
Published: (2020-04-01) -
High-dose methotrexate
by: Manikandan Dhanushkodi
Published: (2019-01-01) -
Genetic polymorphisms as predictors of methotrexate toxicity: literature review
by: G. A. Radzhabova, et al.
Published: (2024-04-01) -
High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights
by: Ana Carolina Nakamura Tome, et al.
Published: (2025-03-01) -
Early toxicity of high-dose methotrexate in the treatment of non-hodgkin lymphomas in children
by: Z. K. Simavonyan, et al.
Published: (2025-03-01)